ATAI Investor Day Presentation Deck

Key Phase 2 and 3 CIAS Programs in Progress Cognition as a Primary Endpoint Boehringer Ingelheim GlyT1 inhibitor Biogen positive allosteric modulator (potentiator) of the a-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor • Neurocrine/Takeda Luvadaxistat (Cognition secondary but changing to primary) ● ● ● Negative Outcome on Primary Endpoint Measured by the Change from Baseline on the Positive and Negative Syndrome Scale/Negative Symptom Factor Score (PANSS NSFS) • Positive Outcome on Cognitive Assessment Secondary Endpoints Support Potential Further Clinical Development of Luvadaxistat Cognition as Secondary Endpoint Several studies but cognition not listed on clinicaltrials.gov Lo Note that many of these programs have specific mechanisms of action while the Recognify compound has a more complex MoA that modulates multiple receptor systems. Other compounds that target multiple receptor systems, such as clozapine, have demonstrated powerful efficacy in schizophrenia. g 18

View entire presentation